Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients

Journal of Human Hypertension volume 28, pages 165–169 (2014)Cite this article

Subjects

Abstract

Tumour necrosis factor-alpha (TNF-α) is an important mediator in the pathogenesis of rheumatoid arthritis (RA) and hypertension. TNF-α inhibitors improve clinical symptoms and inhibit joint destruction in RA, but their effect on blood pressure (BP) has not been fully investigated. We measured 24-h BP using an ambulatory BP monitor in 16 RA patients treated with a TNF-α inhibitor, infliximab, to investigate its influence on BP and its association with the regulatory factors of BP and renin-angiotensin-aldosterone and sympathetic nervous systems. Infliximab significantly reduced the 24-h systolic BP (SBP) from 127.4±21.8 to 120.1±23.4 mm Hg (P<0.0001). Particularly, morning BP (0600–0800 h) decreased from 129.7±19.7 to 116.9±13.4 mm Hg (P<0.0001), and daytime BP decreased from 131.8±15.1 to 122.5±13.7 mm Hg (P<0.0001). Infliximab significantly reduced the plasma level of norepinephrine and plasma renin activity (PRA) (from 347.5±180.7 to 283.0±181.8 pg ml−1 and 2.6±2.7 to 2.1±2.9 ng ml−1 h−1, respectively) but did not significantly reduce the plasma levels of dopamine and epinephrine. The reduction in morning SBP correlated with the reduction in the norepinephrine level (P<0.05) but not with that in PRA and inflammatory parameters related to RA. This study shows the effect of infliximab on ambulatory BP, especially daytime BP, which may be partly accounted for by the reduction of sympathetic nerve activity after infliximab treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, Berneis K et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010; 212: 377–382.

    Article  CAS  PubMed  Google Scholar 

  2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–1307.

    Article  PubMed  Google Scholar 

  3. Ridker PM, Cook N . Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955–1959.

    Article  PubMed  Google Scholar 

  4. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37: 481–494.

    Article  CAS  PubMed  Google Scholar 

  5. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737–2745.

    Article  PubMed  Google Scholar 

  6. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP . Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010–2019.

    Article  PubMed  Google Scholar 

  7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

    Article  PubMed  Google Scholar 

  8. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1477–1482.

    Article  CAS  Google Scholar 

  9. Morrison A, Ramey DR, van Adelsberg J, Watson DJ . Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 2007; 23: 2395–2404.

    Article  CAS  PubMed  Google Scholar 

  10. Rozman B, Praprotnik S, Logar D, Tomsic M, Hojnik M, Kos-Golja M et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61: 567–569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kvien TK, Zeidler HK, Hannonen P, Wollheim FA, Førre O, Hafström I et al. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 2002; 61: 511–516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F . Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–1177.

    Article  CAS  PubMed  Google Scholar 

  13. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B . Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006; 17: S218–S225.

    Article  CAS  PubMed  Google Scholar 

  14. Choy EH, Panayi GS . Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–916.

    Article  CAS  PubMed  Google Scholar 

  15. Kim KI, Lee JH, Chang HJ, Cho YS, Youn TJ, Chung WY et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008; 72: 293–298.

    Article  CAS  PubMed  Google Scholar 

  16. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113–117.

    Article  PubMed  Google Scholar 

  17. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG . Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 272–278.

    CAS  PubMed  Google Scholar 

  18. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rhuem 1993; 36: 1681–1690.

    Article  CAS  Google Scholar 

  19. Elmarakby AA, Quigley JE, Pollock DM, Imig JD . Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 2006; 47: 557–562.

    Article  CAS  PubMed  Google Scholar 

  20. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D . Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25: 644–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012; 126: 2473–2480.

    Article  PubMed  Google Scholar 

  22. Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S . The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum 2012; 42: 1–8.

    Article  CAS  PubMed  Google Scholar 

  23. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010; 69: 1342–1345.

    Article  CAS  PubMed  Google Scholar 

  24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.

    Article  CAS  PubMed  Google Scholar 

  25. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–48.

    Article  CAS  PubMed  Google Scholar 

  26. Ferreri NR, Zhao Y, Takizawa H, McGiff JC . Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens 1997; 15: 1481–1484.

    Article  CAS  PubMed  Google Scholar 

  27. Van Doornum S, McColl G, Wicks IP . Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1428–1432.

    Article  CAS  Google Scholar 

  28. van der Steen MS, Lenders JW, Graafsma SJ, den Arend J, Thien T . Reproducibility of ambulatory blood pressure monitoring in daily practice. J Hum Hypertens 1999; 13: 303–308.

    Article  CAS  PubMed  Google Scholar 

  29. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.

    Article  PubMed  Google Scholar 

  30. Ikeda T, Gomi T, Shibuya Y, Matsuo K, Kosugi T, Oku N et al. Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients. Hypertens Res 2004; 27: 939–946.

    Article  PubMed  Google Scholar 

  31. Kario K . Time for focus on morning hypertension: Pitfall of current antihypertensive medication. Am J Hypertens 2005; 18: 149–151.

    Article  PubMed  Google Scholar 

  32. Zakopoulos NA, Tsivgoulis G, Barlas G, Papamichael C, Spengos K, Manios E et al. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 2005; 45: 505–512.

    Article  CAS  PubMed  Google Scholar 

  33. Kaneda R, Kario K, Hoshide S, Umeda Y, Hoshide Y, Shimada K . Morning blood pressure hyper-reactivity is an independent predictor for hypertensive cardiac hypertrophy in a community-dwelling population. Am J Hypertens 2005; 18: 1528–1533.

    Article  PubMed  Google Scholar 

  34. Maeda K, Yasunari K, Watanabe T, Nakamura M . Oxidative stress by peripheral blood mononuclear cells is increased in hypertensives with an extreme-dipper pattern and/or morning surge in blood pressure. Hypertens Res 2005; 28: 755–761.

    Article  CAS  PubMed  Google Scholar 

  35. Marfella R, Siniscalchi M, Portoghese M, Di Filippo C, Ferraraccio F, Schiattarella C et al. Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. Hypertension 2007; 49: 784–791.

    Article  CAS  PubMed  Google Scholar 

  36. Dixon WG, Watson KD, Lunt M, Hyrich KL . British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP . British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905–2912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83–86.

    CAS  PubMed  Google Scholar 

  38. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 868–872.

    Article  CAS  PubMed  Google Scholar 

  39. Furlan R, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G et al. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation 1990; 81: 537–547.

    Article  CAS  PubMed  Google Scholar 

  40. Portaluppi F, Bagni B, degli Uberti E, Montanari L, Cavallini R, Trasforini G et al. Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects. J Hypertens 1990; 8: 85–95.

    Article  CAS  PubMed  Google Scholar 

  41. Dodt C, Breckling U, Derad I, Fehm HL, Born J . Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension 1997; 30: 71–76.

    Article  CAS  PubMed  Google Scholar 

  42. Panza JA, Epstein SE, Quyyumi AA . Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991; 325: 986–990.

    Article  CAS  PubMed  Google Scholar 

  43. Pickering TG, Levenstein M, Walmsley P . Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens 1994; 7: 844–847.

    Article  CAS  PubMed  Google Scholar 

  44. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43: 169–175.

    Article  CAS  PubMed  Google Scholar 

  45. Takahashi H, Nishimura M, Sakamoto M, Ikegaki I, Nakanishi T, Yoshimura M . Effects of interleukin-1 beta on blood pressure, sympathetic nerve activity, anf pituitary endocrine functions in anesthetized rats. Am J Hypertens 1992; 5: 224–229.

    Article  CAS  PubMed  Google Scholar 

  46. Sriramula S, Haque M, Majid DS, Francis J . Involvement of tumor necrosis factor-alpha in angiotension 2 -mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008; 51: 1345–1351.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine (I), Osaka Medical College, Takatsuki, Japan

    S Yoshida, T Takeuchi, T Kotani, N Yamamoto, K Hata, K Nagai, T Shoda, S Makino & T Hanafusa

  2. Department of Pharmacology, Osaka Medical College, Takatsuki, Japan

    S Takai

Authors
  1. S Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Kotani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Shoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Hanafusa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Takeuchi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshida, S., Takeuchi, T., Kotani, T. et al. Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens 28, 165–169 (2014). https://doi.org/10.1038/jhh.2013.80

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2013.80

Keywords

This article is cited by

Search

Advanced search

Quick links